A Patient with Stage IV Gastric Cancer Survived for 5 Years after Long-term Chemotherapy Based on Nab-paclitaxel
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
A 78-year-old man underwent R0 resection for gastric cancer with solitary peritoneal metastasis.Postoperatively, first-line therapy was capecitabine/cisplatin, followed by weekly nab-paclitaxel (nab-PTX) as second-line therapy.After 22 courses, weekly nab-PTX therapy was halted due to no visible lesions.Two years later, peritoneal and lung metastases appeared, after S-1/oxaliplatin therapy, weekly nab-PTX/ramucirumab therapy was restarted.After 18 courses, all lesions disappeared but reappeared 4 months later.Weekly nab-PTX/ramucirumab therapy was restarted, and after nine courses, all metastases disappeared.The nab-PTX dosage was reduced from 90 to 40 mg/m 2 /day due to adverse events.The patient survived 5 years and 9 months post-surgery and 2 years and 9 months post-recurrence.As far as searched, the total number of nab-PTX administrations was 141, the highest for elderly patients treated with nab-PTX.By adjusting the dosage and monitoring adverse events, long-term chemotherapy based on nab-PTX could lead to long-term survival in elderly patients recurrent with gastric cancer.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
Où se fait cette recherche
-
Toho University Department of Surgical Pathology pays non établi dans la noticeUniversité ou école supérieure
-
Toho University Omori Medical Center pays non établi dans la noticeÉtablissement de santé
-
Tohoku University pays non établi dans la noticeUniversité ou école supérieure
-
Graduate School of Medicine Department of Clinical Oncology pays non établi dans la noticeUniversité ou école supérieure
Department of Surgical Pathology — Toho University, Toho University Omori Medical Center et Tohoku University, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.